Guardant Health's AI Data Supports ENHERTU Approval

Precision oncology company's real-world evidence backs expanded use of HER2-positive cancer drug.

Mar. 30, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

Guardant Health, a leading precision oncology company, announced that real-world evidence generated from its InfinityAI platform supported the approval of ENHERTU, a drug for previously treated patients with HER2-positive breast cancer. The data provided additional clinical insights to help expand the approved use of the medication.

Why it matters

This development demonstrates how AI-powered real-world data can accelerate the approval process for new cancer treatments, potentially getting life-saving drugs to patients faster. Guardant's platform leverages a large database of clinical information to generate evidence that complements traditional clinical trials.

The details

Guardant Health's InfinityAI platform analyzed real-world data on the use of ENHERTU, an antibody-drug conjugate approved for HER2-positive breast cancer. The findings from this real-world evidence supported the expanded approval of ENHERTU to treat previously treated patients with HER2-positive metastatic breast cancer.

  • The data was announced on March 30, 2026.

The players

Guardant Health, Inc.

A leading precision oncology company that provides cancer screening and monitoring tests using advanced genomic and AI technologies.

ENHERTU

An antibody-drug conjugate approved for the treatment of HER2-positive breast cancer.

Got photos? Submit your photos here. ›

The takeaway

Guardant Health's real-world data platform is demonstrating its value in accelerating the approval of innovative cancer treatments, which could lead to faster access for patients in need.